Category Archives: Patents

UPenn, Nationwide Children’s Hospital refuse to disclose which patents they licensed to Novartis for Zolgensma

Source: Keionline 25th June, 2019   Zolgensma, Novartis’s new $2.1 million gene therapy for children with spinal muscular atrophy (SMA), is a remarkable breakthrough with a steep price tag: the cost per child is $2.125 million. The treatment was developed using … Continue reading

Posted in Patents | Leave a comment

Proposed patent legislation would block research, stifle innovation, and harm patients

Source: Statnews 7th June, 2019   U.S. Senator Thom Tillis is among several members of Congress seeking to change the Patent Act.ALEX WONG/GETTY IMAGES In 2013, the U.S. Supreme Court ruled in favor of innovation when it struck down a patent … Continue reading

Posted in Patents | Leave a comment

“Indian CSO letter to the DPIIT on the proposed amendment to the Patent Rules”

20th May, 2019   New Delhi 16 May 2019 To Shri Ramesh Abhishek Secretary, Department for Promotion of Industry and Internal Trade, Ministry of Commerce & Industry, Room No.157 Udyog Bhawan, New Delhi Telephone : 2306 1815, 2306 1667, 23061598(F) … Continue reading

Posted in Fast track patent examination, Indian Patent Law, Patent examination system, Sec 3 (d) | Leave a comment

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

The grounds for opposing patent applications for velpatasvir

Source: MSF | July 09, 2018 Gilead Sciences has applied for multiple patents on oral hepatitis C medicines – sofosbuvir and velpatasvir in India: not only limiting itself to basic patents but also staking claims on a number of additional … Continue reading

Posted in Patent linkage, Patent Opposition, Patent Term Extension, Patents | Leave a comment

The switch from patents to state-dependent prizes for technological innovation

by Hwan C. Lin, Journal of Macroeconomics Volume 50, December 2016, Pages 193-223 Highlights •Examine the intertemporal bounty (IB) system as an alternative to patents. •The IB system rewards innovation with a bounty claim to state-dependent prizes (called “intertemporal bounties”) over time. … Continue reading

Posted in Innovation, Patent, Patent examination system, Uncategorized | Leave a comment

The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system

by Tahir Amin, CNBC | June 27, 2018 One in four Americans are unable to fill prescriptions due to high prices. Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices. Until the … Continue reading

Posted in Evergreening, Patent, Patent examination system, Patent Opposition, Uncategorized | Leave a comment